IDH1 and acute myeloid leukemia: Ivosidenib – an oral, targeted, small‐molecule inhibitor of mutant IDH1 – has been evaluated as a single agent in a Phase 1 study in relapsed or refractory (R/R) AML with IDH1 mutation [53].